Tagrisso 인터넷 바카라 사이트 achieves landmark 4-year lung cancer survival…Asian subgroup findings should avoid overinterpretation

[by Lee, Young Sung] The combination of Tagrisso (osimertinib) and chemotherapy represents a pivotal advancement in the history of lung cancer treatment, yielding evidence of a median overall survival (mOS) of four years. Findings from the Phase 3 clinical trial (FLAURA2) demonstrated that the Tagrisso combination prolonged mOS by nearly 10 months compared with Tagrisso monotherapy, the current standard of care.

AstraZeneca (AZ), the developer, underscored that the OS outcomes reflect a robust and definitive measure, supported by a data maturity of 57%. Notably, the company highlighted the adaptive trial design of the Tagrisso 인터넷 바카라 사이트 (approximately 8 months) + Tagrisso monotherapy (long-term maintenance) and emphasized its favorable tolerability profile, positioning it as a highly applicable option in clinical practice.

Moreover, with respect to the OS findings indicating a hazard ratio (HR) of 1.0 in the Asian subgroup excluding Chinese patients, the company advised caution in overinterpretation, characterizing the result as a ‘statistic derived from a small population.’

On September 9, Leora Horn, Senior Vice President of Late Development Oncology at AstraZeneca, conveyed these remarks in an interview during the World Conference on 인터넷 바카라 사이트 Cancer (WCLC 2025) in Barcelona, ​​Spain, coinciding with the presentation of the data.

In reference to comparisons with data from the competing Phase 3 MARIPOSA trial, Horn stated, "The overall survival (OS) outcome from FLAURA2 represents a definitive value, whereas MARIPOSA remains an estimate. At this point, FLAURA2 has higher clinical reliability." The MARIPOSA trial projects that the lazertinib + Rybrevant 인터넷 바카라 사이트 may extend OS by more than a year compared to Tagrisso monotherapy. However, median overall survival (mOS) has not yet been reached.

"Whereas medical education once taught that the average survival time for lung cancer was less than a 인터넷 바카라 사이트, achieving a four-인터넷 바카라 사이트 OS represents an extraordinary advancement," Horn emphasized.

◇"FLAURA2: Advantages in flexibility and tolerability"

Horn also highlighted the flexibility and tolerability of the FLAURA2 trial as additional strengths.

"Pemetrexed, one of the chemotherapy agents administered in 인터넷 바카라 사이트 with Tagrisso, is often described as a 'water-like anticancer drug' characterized by minimal adverse effects and the absence of hair loss or skin rashes," she further remarked. "In clinical practice, such tolerability is a crucial factor for patients with EGFR-mutated lung cancer, particularly women."

"Tagrisso is already a well-established treatment in clinical practice, and the significance of the FLAURA2 인터넷 바카라 사이트 therapy lies in leveraging this familiarity to develop a treatment strategy that patients can more easily accept," Horn emphasized. She explained that the regimen is well-tolerated and easy to implement in real-world clinical settings.

◇Non-Chinese Asians HR=1.0…“Caution advised for overinterpretation in subgroup statistics”

Regarding the OS hazard ratio (HR) of 1.0 observed in the non-Chinese Asian subgroup, she explained, "Excluding Chinese patients, the Asian subgroup including patients from multiple countries such as Korea, Taiwan, and Vietnam, represents a relatively small cohort in comparison to the overall population."

"It is important not to overinterpret the findings from these subgroup analyses," she further added. "At this stage, no definitive clinical hypothesis accounts for the observed difference, and we are considering multiple possibilities, including variations in toxicity or the impact of subsequent treatment sequences."

"In conclusion, based on the data available to date, no direct limitations or changes have been identified in the clinical reliability or treatment practices of Asian physicians with respect to the FLAURA2 인터넷 바카라 사이트 therapy. Therefore, we consider it unlikely that serious concerns will arise," Horn emphasized.